Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?

@article{Nocturne2017DoesTR,
  title={Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?},
  author={Ga{\'e}tane Nocturne and Rapha{\'e}le Seror and Xavier Mariette},
  journal={Annals of the rheumatic diseases},
  year={2017},
  volume={76 2},
  pages={
          e3
        }
}
We read with interest the paper by Mercer et al 1 focusing on the risk of lymphoma in patients included in the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA) and treated with tumour necrosis factor inhibitors (TNFi). Based on data from a prospective cohort including >120 000 patient-years of exposure to TNFi or conventional synthetic disease-modifying drugs (csDMARDs), the authors pointed out that treatment with TNFi in patients with RA was not… CONTINUE READING

Citations

Publications citing this paper.

Lymphome bei rheumatischen Erkrankungen

  • Zeitschrift für Rheumatologie
  • 2017
VIEW 8 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 12 REFERENCES

Comparison of the one and 5 - years effectiveness of adalimumab , etanercept and ustekinumab in psoriasis patients in daily clinical practice : Results from the prospective BioCAPTURE registry

J Zweegers, JM Groenewoud, JM vandenReek
  • Br J Dermatol
  • 2016

Drug - speci fi c risk of nontuberculosis opportunistic infections in patients receiving antiTNF therapy reported to the 3 - year prospective French RATIO registry

D Salmon-Ceron, F Tubach, O Lortholary
  • Ann Rheum Dis
  • 2011